Aspen Aerogels Inc Financials
Aspen Aerogels Inc (ASPN) reported $271.1M in revenue for fiscal year 2025, down 40.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 became a cash-preservation year as sales and margin structure reset lower but liquidity still held.
In FY2025, cash conversion separated from accounting profit: a-$389.6M net loss still coexisted with$32.9M of operating cash flow. Because capex fell sharply from FY2024 and both receivables and inventory came down, the year reads as a cash-release reset after prior expansion rather than an equally large cash drain.
The drop from
Even after the reset, liquidity stayed comfortable:
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Aspen Aerogels Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Aspen Aerogels Inc's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 16/100.
Aspen Aerogels Inc's revenue declined 40.1% year-over-year, from $452.7M to $271.1M. This contraction results in a growth score of 56/100.
Aspen Aerogels Inc carries a low D/E ratio of 0.28, meaning only $0.28 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 70/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.90, Aspen Aerogels Inc holds $3.90 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 85/100.
While Aspen Aerogels Inc generated $32.9M in operating cash flow, capex of $37.4M consumed most of it, leaving -$4.6M in free cash flow. This results in a low score of 12/100, reflecting heavy capital investment rather than weak cash generation.
Aspen Aerogels Inc posts a -165.4% return on equity (ROE), meaning it loses $165 for every $100 of shareholders' equity. This results in a returns score of 13/100. This is down from 2.2% the prior year.
Aspen Aerogels Inc scores -3.98, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($429.9M) relative to total liabilities ($171.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Aspen Aerogels Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Aspen Aerogels Inc reported a net loss of $389.6M while generating $32.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Aspen Aerogels Inc reported an operating loss of $378.2M against $7.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Aspen Aerogels Inc generated $271.1M in revenue in fiscal year 2025. This represents a decrease of 40.1% from the prior year.
Aspen Aerogels Inc's EBITDA was -$333.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 532.2% from the prior year.
Aspen Aerogels Inc reported -$389.6M in net income in fiscal year 2025. This represents a decrease of 3012.5% from the prior year.
Aspen Aerogels Inc earned -$4.73 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 2882.4% from the prior year.
Cash & Balance Sheet
Aspen Aerogels Inc recorded an outflow of $4.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 88.8% from the prior year.
Aspen Aerogels Inc held $156.9M in cash against $65.5M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Aspen Aerogels Inc's gross margin was 17.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 23.4 percentage points from the prior year.
Aspen Aerogels Inc's ROE was -165.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 167.6 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Aspen Aerogels Inc invested $13.4M in research and development in fiscal year 2025. This represents a decrease of 25.7% from the prior year.
Aspen Aerogels Inc invested $37.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 56.6% from the prior year.
Not reported for fiscal year 2025.
ASPN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $202.1M | $271.1M-40.1% | $452.7M+89.6% | $238.7M+32.4% | $180.4M+48.3% | $121.6M+21.3% | $100.3M-28.1% | $139.4M+33.6% | $104.4M-6.5% | $111.6M-5.2% | $117.7M-3.9% | $122.5M+19.6% | $102.4M+18.9% | $86.1M+35.7% | $63.5M |
| Cost of Revenue | $196.7M | $225.1M-16.6% | $269.8M+48.4% | $181.8M+3.7% | $175.4M+57.0% | $111.7M+30.4% | $85.7M | N/A | N/A | $92.1M-1.2% | $93.1M-3.9% | $96.9M+15.8% | $83.7M+14.0% | $73.4M+4.8% | $70.0M |
| Gross Profit | $5.4M | $46.0M-74.9% | $182.9M+221.3% | $56.9M+1043.9% | $5.0M-49.9% | $9.9M-31.9% | $14.6M-44.5% | $26.3M+107.5% | $12.7M-32.1% | $18.7M-19.9% | $23.3M-5.4% | $24.6M+44.3% | $17.1M+59.2% | $10.7M+234.7% | -$8.0M |
| R&D Expenses | $11.2M | $13.4M-25.7% | $18.1M+10.4% | $16.4M-3.4% | $16.9M+48.0% | $11.4M+31.1% | $8.7M+3.8% | $8.4M+33.0% | $6.3M+2.2% | $6.2M+16.5% | $5.3M+1.0% | $5.3M-12.2% | $6.0M+15.9% | $5.2M+0.3% | $5.1M |
| SG&A Expenses | $57.2M | $55.8M-21.6% | $71.1M+25.3% | $56.8M+47.4% | $38.5M+71.0% | $22.5M+43.6% | $15.7M-4.8% | $16.5M-13.8% | $19.1M+0.5% | $19.0M+9.2% | $17.4M+15.6% | $15.1M-10.6% | $16.9M+31.3% | $12.8M+13.6% | $11.3M |
| Operating Income | -$123.3M | -$378.2M-793.6% | $54.5M+210.8% | -$49.2M+37.9% | -$79.2M-95.2% | -$40.6M-88.2% | -$21.6M-52.3% | -$14.2M+58.3% | -$33.9M-77.2% | -$19.1M-70.6% | -$11.2M-80.0% | -$6.2M+61.1% | -$16.0M+19.7% | -$20.0M+39.4% | -$33.0M |
| Interest Expense | N/A | $7.5M+31.6% | $5.7M-34.5% | $8.7M+411.8% | $1.7M+148.6% | -$3.5M-1650.0% | -$200K+50.0% | -$400K+20.0% | -$500K-150.0% | -$200K | N/A | N/A | -$50.3M-64.3% | -$30.6M-40.4% | -$21.8M |
| Income Tax | $863K | $2.4M+39.7% | $1.7M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$126.2M | -$389.6M-3012.5% | $13.4M+129.2% | -$45.8M+44.6% | -$82.7M-123.0% | -$37.1M-70.1% | -$21.8M-49.7% | -$14.6M+57.7% | -$34.4M-78.3% | -$19.3M-60.7% | -$12.0M-87.4% | -$6.4M+90.3% | -$66.3M-39.3% | -$47.6M+15.2% | -$56.1M |
| EPS (Diluted) | — | -$4.73-2882.4% | $0.17+125.8% | -$0.66 | -$2.10 | -$1.22-47.0% | -$0.83 | N/A | N/A | N/A | N/A | -$0.28 | -$5.37 | $410.56+114.4% | -$2851.08 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ASPN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $406.7M-54.6% | $895.1M+27.3% | $703.0M+9.3% | $643.4M+251.7% | $183.0M+87.8% | $97.4M-5.9% | $103.5M+4.5% | $99.0M-20.0% | $123.8M-8.1% | $134.7M-3.9% | $140.1M-3.4% | $145.0M+60.7% | $90.2M | N/A |
| Current Assets | $242.1M-40.9% | $409.4M+53.7% | $266.3M-28.0% | $369.7M+229.6% | $112.2M+138.0% | $47.1M+3.0% | $45.8M+22.9% | $37.3M-21.8% | $47.7M-5.0% | $50.2M-18.6% | $61.6M-16.0% | $73.4M+161.9% | $28.0M | N/A |
| Cash & Equivalents | $156.9M-29.0% | $220.9M+58.1% | $139.7M-50.3% | $281.3M+267.5% | $76.6M+364.1% | $16.5M+354.1% | $3.6M+9.2% | $3.3M-68.9% | $10.7M-40.9% | $18.1M-44.9% | $32.8M-34.0% | $49.7M+3058.8% | $1.6M+17.2% | $1.3M |
| Inventory | $38.2M-19.6% | $47.6M+21.3% | $39.2M+73.9% | $22.5M+88.0% | $12.0M-8.5% | $13.1M+49.4% | $8.8M+19.8% | $7.3M-17.9% | $8.9M-30.7% | $12.9M+97.0% | $6.5M+33.4% | $4.9M-28.9% | $6.9M | N/A |
| Accounts Receivable | $35.3M-67.7% | $109.1M+55.9% | $70.0M+22.0% | $57.4M+180.8% | $20.4M+30.1% | $15.7M-51.3% | $32.3M+26.2% | $25.6M-4.5% | $26.8M+52.6% | $17.5M-15.0% | $20.6M+15.1% | $17.9M-4.5% | $18.8M | N/A |
| Total Liabilities | $171.2M-39.0% | $280.4M+30.4% | $215.0M+9.7% | $196.0M+259.3% | $54.5M+84.5% | $29.6M-33.6% | $44.5M+54.7% | $28.8M+25.8% | $22.9M+19.7% | $19.1M+8.6% | $17.6M-17.5% | $21.3M-86.0% | $152.2M | N/A |
| Current Liabilities | $62.0M-43.7% | $110.1M+41.0% | $78.1M-1.1% | $78.9M+116.0% | $36.6M+162.5% | $13.9M-54.2% | $30.4M+31.9% | $23.1M+6.9% | $21.6M+19.0% | $18.1M+4.1% | $17.4M-13.9% | $20.2M-35.6% | $31.4M | N/A |
| Long-Term Debt | $65.5M-31.1% | $95.0M | N/A | N/A | N/A | $2.1M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $235.5M-61.7% | $614.7M+25.9% | $488.1M+9.1% | $447.4M+248.4% | $128.4M+89.2% | $67.9M+15.0% | $59.0M-16.0% | $70.3M-30.4% | $100.9M-12.7% | $115.6M-5.6% | $122.5M-1.0% | $123.7M+299.7% | -$62.0M+48.7% | -$120.8M |
| Retained Earnings | -$1.0B-59.0% | -$660.2M+2.0% | -$673.6M-7.3% | -$627.8M-15.2% | -$545.1M-7.3% | -$508.0M-4.5% | -$486.1M-3.1% | -$471.6M-7.9% | -$437.1M-4.7% | -$417.5M-3.0% | -$405.5M-1.6% | -$399.1M-19.9% | -$332.8M | N/A |
Not reported in any period shown, so not listed: Goodwill.
ASPN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $49.1M | $32.9M-27.8% | $45.5M+206.9% | -$42.6M+54.9% | -$94.4M-406.8% | -$18.6M-87.7% | -$9.9M-841.6% | -$1.1M+87.8% | -$8.7M-87.9% | -$4.6M-696.9% | -$578K-110.8% | $5.4M-19.4% | $6.6M+148.6% | -$13.7M+47.1% | -$25.9M |
| Capital Expenditures | $14.7M | $37.4M-56.6% | $86.3M-50.8% | $175.5M-1.4% | $178.0M+1191.7% | $13.8M+303.3% | $3.4M+61.7% | $2.1M-41.2% | $3.6M-41.3% | $6.1M-53.7% | $13.2M-39.8% | $22.0M+65.8% | $13.2M+297.7% | $3.3M-67.5% | $10.2M |
| Free Cash Flow | $34.4M | -$4.6M+88.8% | -$40.7M+81.3% | -$218.1M+19.9% | -$272.4M-740.5% | -$32.4M-142.9% | -$13.3M-321.4% | -$3.2M+74.1% | -$12.2M-14.2% | -$10.7M+22.3% | -$13.8M+16.9% | -$16.6M-151.7% | -$6.6M+61.3% | -$17.0M+52.9% | -$36.1M |
| Investing Cash Flow | -$14.7M | -$37.4M+56.6% | -$86.3M+50.8% | -$175.5M+1.4% | -$178.0M-1191.7% | -$13.8M-303.3% | -$3.4M-61.7% | -$2.1M+41.2% | -$3.6M+41.3% | -$6.1M+53.7% | -$13.2M | N/A | N/A | N/A | N/A |
| Financing Cash Flow | -$49.0M | -$58.1M-147.6% | $122.0M+61.7% | $75.5M-84.2% | $478.4M+417.3% | $92.5M+252.9% | $26.2M+654.7% | $3.5M-28.9% | $4.9M+46.5% | $3.3M+460.6% | -$924K | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ASPN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 17.0%-23.4pp | 40.4%+16.6pp | 23.8%+21.1pp | 2.8%-5.4pp | 8.2%-6.4pp | 14.5%-4.3pp | 18.9%+6.7pp | 12.1%-4.6pp | 16.7%-3.1pp | 19.8%-0.3pp | 20.1%+3.4pp | 16.7%+4.2pp | 12.5%+25.0pp | -12.6% |
| Operating Margin | -139.5% | 12.0%+32.7pp | -20.6%+23.3pp | -43.9%-10.6pp | -33.4%-11.9pp | -21.5%-11.4pp | -10.2%+22.3pp | -32.5%-15.4pp | -17.1%-7.6pp | -9.5%-4.4pp | -5.1%+10.6pp | -15.7%+7.5pp | -23.2%+28.8pp | -52.0% |
| Net Margin | -143.7% | 2.9%+22.1pp | -19.2%+26.7pp | -45.9%-15.4pp | -30.5%-8.8pp | -21.8%-11.3pp | -10.4%+22.6pp | -33.0%-15.7pp | -17.3%-7.1pp | -10.2%-5.0pp | -5.2%+59.5pp | -64.8%-9.5pp | -55.3%+33.2pp | -88.5% |
| Return on Equity | -165.4%-167.6pp | 2.2%+11.6pp | -9.4%+9.1pp | -18.5%+10.4pp | -28.9%+3.3pp | -32.1%-7.5pp | -24.7%+24.3pp | -49.0%-29.9pp | -19.1%-8.7pp | -10.4%-5.2pp | -5.2%+48.4pp | -53.6% | N/A | N/A |
| Return on Assets | -95.8%-97.3pp | 1.5%+8.0pp | -6.5%+6.3pp | -12.9%+7.4pp | -20.3%+2.1pp | -22.4%-8.3pp | -14.1%+20.7pp | -34.8%-19.2pp | -15.6%-6.7pp | -8.9%-4.4pp | -4.6%+41.1pp | -45.7%+7.0pp | -52.8% | N/A |
| Current Ratio | 3.90+0.2x | 3.72+0.3x | 3.41-1.3x | 4.68+1.6x | 3.07-0.3x | 3.38+1.9x | 1.50-0.1x | 1.61-0.6x | 2.21-0.6x | 2.77-0.8x | 3.54-0.1x | 3.63+2.7x | 0.89 | N/A |
| Debt-to-Equity | 0.28+0.1x | 0.15-0.3x | 0.440.0x | 0.440.0x | 0.42+0.4x | 0.03-0.7x | 0.75+0.3x | 0.41+0.2x | 0.23+0.1x | 0.170.0x | 0.140.0x | 0.17 | N/A | N/A |
| FCF Margin | -1.7%+7.3pp | -9.0%+82.4pp | -91.3% | -151.0% | -26.6%-13.3pp | -13.3%-11.0pp | -2.3%+9.5pp | -11.7%-2.1pp | -9.6%+2.1pp | -11.7%+1.8pp | -13.6%-7.1pp | -6.4%+13.3pp | -19.8%+37.2pp | -56.9% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Aspen Aerogels Inc Ranks
Frequently Asked Questions
What is Aspen Aerogels Inc's annual revenue?
Aspen Aerogels Inc (ASPN) reported $271.1M in total revenue for fiscal year 2025. This represents a -40.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Aspen Aerogels Inc's revenue growing?
Aspen Aerogels Inc (ASPN) revenue declined by 40.1% year-over-year, from $452.7M to $271.1M in fiscal year 2025.
Is Aspen Aerogels Inc profitable?
No, Aspen Aerogels Inc (ASPN) reported a net income of -$389.6M in fiscal year 2025.
What is Aspen Aerogels Inc's EBITDA?
Aspen Aerogels Inc (ASPN) had EBITDA of -$333.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Aspen Aerogels Inc have?
As of fiscal year 2025, Aspen Aerogels Inc (ASPN) had $156.9M in cash and equivalents against $65.5M in long-term debt.
What is Aspen Aerogels Inc's gross margin?
Aspen Aerogels Inc (ASPN) had a gross margin of 17.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Aspen Aerogels Inc's return on equity (ROE)?
Aspen Aerogels Inc (ASPN) has a return on equity of -165.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Aspen Aerogels Inc's free cash flow?
Aspen Aerogels Inc (ASPN) recorded an outflow of $4.6M in free cash flow during fiscal year 2025. This represents a 88.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aspen Aerogels Inc's operating cash flow?
Aspen Aerogels Inc (ASPN) generated $32.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Aspen Aerogels Inc's total assets?
Aspen Aerogels Inc (ASPN) had $406.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Aspen Aerogels Inc's capital expenditures?
Aspen Aerogels Inc (ASPN) invested $37.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Aspen Aerogels Inc spend on research and development?
Aspen Aerogels Inc (ASPN) invested $13.4M in research and development during fiscal year 2025.
What is Aspen Aerogels Inc's current ratio?
Aspen Aerogels Inc (ASPN) had a current ratio of 3.90 as of fiscal year 2025, which is generally considered healthy.
What is Aspen Aerogels Inc's debt-to-equity ratio?
Aspen Aerogels Inc (ASPN) had a debt-to-equity ratio of 0.28 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aspen Aerogels Inc's return on assets (ROA)?
Aspen Aerogels Inc (ASPN) had a return on assets of -95.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Aspen Aerogels Inc's Altman Z-Score?
Aspen Aerogels Inc (ASPN) has an Altman Z-Score of -3.98, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Aspen Aerogels Inc's Piotroski F-Score?
Aspen Aerogels Inc (ASPN) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aspen Aerogels Inc's earnings high quality?
Aspen Aerogels Inc (ASPN) reported a net loss of $389.6M while generating $32.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Aspen Aerogels Inc cover its interest payments?
Aspen Aerogels Inc (ASPN) reported an operating loss of $378.2M against $7.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Aspen Aerogels Inc?
Aspen Aerogels Inc (ASPN) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.